1988
DOI: 10.1016/s0006-291x(88)81196-3
|View full text |Cite
|
Sign up to set email alerts
|

Dexamethasone inhibits the cytotoxic activity of tumor necrosis factor

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
10
0

Year Published

1989
1989
1996
1996

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 22 publications
(12 citation statements)
references
References 28 publications
2
10
0
Order By: Relevance
“…It has been reported that actions of DM such as TNF receptor down-modulation (Kull, 1988) and phospholipase-A2 inhibition (Neale et al, 1988) decrease the TNF susceptibility of cells (Tsujimoto et al, 1988); and in this study we noticed that the IC,, increased approximately 2-fold in L-M cells treated with DM. In LM(pNTnF) cells, after induction of enTNF by DM, the IC,, value increased approximately 5-to 14-fold.…”
Section: Discussionsupporting
confidence: 66%
“…It has been reported that actions of DM such as TNF receptor down-modulation (Kull, 1988) and phospholipase-A2 inhibition (Neale et al, 1988) decrease the TNF susceptibility of cells (Tsujimoto et al, 1988); and in this study we noticed that the IC,, increased approximately 2-fold in L-M cells treated with DM. In LM(pNTnF) cells, after induction of enTNF by DM, the IC,, value increased approximately 5-to 14-fold.…”
Section: Discussionsupporting
confidence: 66%
“…Quinacrine was the most effective inhibitor of cell destruction, followed by hydrocortisone, dexamethasone, and indomethacin. Other investigators have also found that these inhibitors block TNF-induced cytotoxicity, with even more potent effects (close to 100% inhibition of cytotoxicity) (Abe et al, 1988;Tsujimoto et al, 1988). These inhibitor studies rule out the possibility that PLase activation occurs after cell destruction as a result of death.…”
Section: Discussionmentioning
confidence: 90%
“…The narrow therapeutic index of TNF-o~ has encouraged the development of strategies to diminish toxicity while hopefully preserving antitumor activity. Several approaches include use of continuous infusions (13), glucocorticoids (14), inhibitors of prostaglandin synthesis (15), scavengers of oxygen radicals (16), and combining TNF-ot with cytotoxic chemotherapy (17) or other cytokines (18). Toxicity still remains the most significant limitation to TNF-c~ therapeutic utility.…”
Section: Sul-lrlmarymentioning
confidence: 99%